- Home
- COHN vs INAB Comparison
COHN vs INAB Comparison
Compare COHN & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COHN
- INAB
- Stock Information
- Founded
- COHN 1999
- INAB 2016
- Country
- COHN United States
- INAB United States
- Employees
- COHN N/A
- INAB N/A
- Industry
- COHN Investment Bankers/Brokers/Service
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- COHN Finance
- INAB Health Care
- Exchange
- COHN Nasdaq
- INAB Nasdaq
- Market Cap
- COHN 17.9M
- INAB 14.5M
- IPO Year
- COHN N/A
- INAB 2021
- Fundamental
- Price
- COHN $8.51
- INAB $2.18
- Analyst Decision
- COHN
- INAB Strong Buy
- Analyst Count
- COHN 0
- INAB 2
- Target Price
- COHN N/A
- INAB $108.00
- AVG Volume (30 Days)
- COHN 3.8K
- INAB 409.0K
- Earning Date
- COHN 08-04-2025
- INAB 08-07-2025
- Dividend Yield
- COHN 11.47%
- INAB N/A
- EPS Growth
- COHN N/A
- INAB N/A
- EPS
- COHN N/A
- INAB N/A
- Revenue
- COHN $84,171,000.00
- INAB N/A
- Revenue This Year
- COHN N/A
- INAB N/A
- Revenue Next Year
- COHN N/A
- INAB N/A
- P/E Ratio
- COHN N/A
- INAB N/A
- Revenue Growth
- COHN N/A
- INAB N/A
- 52 Week Low
- COHN $6.10
- INAB $2.06
- 52 Week High
- COHN $11.52
- INAB $29.97
- Technical
- Relative Strength Index (RSI)
- COHN 58.24
- INAB 26.80
- Support Level
- COHN $7.97
- INAB $2.06
- Resistance Level
- COHN $8.33
- INAB $4.17
- Average True Range (ATR)
- COHN 0.17
- INAB 0.41
- MACD
- COHN 0.06
- INAB -0.10
- Stochastic Oscillator
- COHN 73.03
- INAB 5.61
About COHN Cohen & Company Inc.
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.